Watch MS experts share their first-hand experience of how their patients have been able to start receiving KESIMPTA and about what treatment is really like for those patients with MS.
Where does KESIMPTA fit in clinical practice? Real-world evidence from the National Hospital for Neurology and Neurosurgery (NHNN), London
Watch Consultant Neurologist Dr Wallace Brownlee as he shares his centre’s first experiences of using KESIMPTA for 42 patients. Dr Brownlee then looks in particular detail at three of the cases, and also describes the important decision-making process for those patients at various points in their treatment course.
How have patients been initiated onto and responded to KESIMPTA? A nursing perspective and insights so far
Watch Consultant MS Nurse Noreen Baker share how she and her team at NHNN set up the KESIMPTA service, how treatment with KESIMPTA was initiated and received, her experience with using KESIMPTA from a nurse’s point of view, and her key learnings about the service so far.
KESIMPTA service in Sheffield and South Yorkshire
Watch Consultant Neurologist Dr David Paling share how KESIMPTA is offered from his centre in Sheffield, by utilising telemedicine through KesimptaConnect, in order to maximise access to KESIMPTA for his patients. Dr Paling goes on to describe the safety and tolerability of KESIMPTA for the patients in his care, as compared to that which is published in clinical trials.
These meetings were organised and funded by Novartis Pharmaceuticals UK Ltd. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
MS, multiple sclerosis.
